文献速递预防保健、筛查与疫苗常见症状与未分化疾病

新冠mRNA疫苗接种后心肌炎与心包炎:发生率、危险因素、自然史与假说机制

Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
PubMed 文献 · BMJ · 2022-07-13

该文综合了2020年10月至2022年1月的证据,发现mRNA疫苗接种后心肌炎发生率在12-17岁男性(50-139例/百万)和18-29岁男性(28-147例/百万)最高。多数病例为男性青少年和年轻成人,在第二剂后2-4天发病,短期病程良性,但长期随访数据有限。

要点

  • 12-17岁和18-29岁男性接种mRNA疫苗后心肌炎发生率最高。
  • 18-29岁人群接种Moderna疫苗后心肌炎发生率可能高于辉瑞疫苗。
  • 两剂间隔≥31天可能降低心肌炎或心包炎发生率,男性18-29岁或需≥56天。

核心结论

  • 青少年和年轻成年男性是mRNA疫苗接种后心肌炎的最高风险人群。
  • 对该人群,选用辉瑞疫苗而非Moderna疫苗、两剂间隔超过30天可能更可取。
  • 5-11岁儿童心肌炎发生率非常罕见,但证据确定性低。
  • mRNA相关心肌炎的临床病程看似良性,但长期随访数据有限。

研究设计与样本

  • 活证据合成与综述,检索Medline、Embase和Cochrane Library(2020年10月6日至2022年1月10日)。
  • 纳入46项研究:14项 incidence、7项危险因素、11项特征与短期病程、3项长期结局、21项机制。
  • 使用改良Joanna Briggs Institute工具进行偏倚风险评估,采用GRADE评级证据确定性。

主要发现

  • 12-17岁男性心肌炎发生率为50-139例/百万(低确定性),18-29岁男性为28-147例/百万(中等确定性)。
  • 5-11岁男孩和女孩及18-29岁女性接种BNT162b2后心肌炎发生率可能少于20例/百万(低确定性)。
  • 在青少年和成人中,大多数(>90%)心肌炎病例为男性,中位年龄20-30岁,症状在第二剂后2-4天出现(71-100%)。
  • 多数患者住院(≥84%),住院时间短(2-4天)。
  • 三项长期随访(3个月;n=38)病例系列提示超过50%的患者存在持续性超声心动图异常、持续症状或需要药物治疗或活动限制。

关键数值与推荐

  • 18-29岁人群接种Moderna疫苗后心肌炎发生率可能高于辉瑞疫苗(中等确定性)。
  • 12-17岁、18-29岁或18-39岁人群,第二剂与第一剂间隔≥31天相比≤30天,心肌炎或心包炎发生率可能更低(低确定性)。
  • 18-29岁男性数据提示,剂量间隔可能需要增加至≥56天以大幅降低心肌炎或心包炎发生率。

临床怎么用

  • 对青少年和年轻成年男性接种mRNA疫苗时,可考虑选用辉瑞疫苗并延长两剂间隔(如≥31天,特定人群≥56天)。
  • 接种后2-4天出现胸痛等症状的年轻男性应警惕心肌炎,但多数短期病程良性。
  • 对5-11岁儿童,心肌炎风险非常低,接种决策可参考低确定性证据。

局限性

  • 5-11岁年龄组仅有1项小样本病例系列(n=8)提供临床病程数据。
  • 心包炎数据有限,患者年龄、性别、发病时间和住院率变异较大。
  • 长期随访数据有限(仅3项病例系列,n=38,随访3个月)。
  • 16种假说机制缺乏直接支持或反驳证据。
  • 临床危险因素数据非常有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To synthesise evidence on incidence rates and risk factors for myocarditis and pericarditis after use of mRNA vaccination against covid-19, clinical presentation, short term and longer term outcomes of cases, and proposed mechanisms. DESIGN: Living evidence syntheses and review. DATA SOURCES: Medline, Embase, and the Cochrane Library were searched from 6 October 2020 to 10 January 2022; reference lists and grey literature (to 13 January 2021). One reviewer completed screening and another verified 50% of exclusions, using a machine learning program to prioritise records. A second reviewer verified all exclusions at full text, extracted data, and (for incidence and risk factors) risk of bias assessments using modified Joanna Briggs Institute tools. Team consensus determined certainty of evidence ratings for incidence and risk factors using GRADE (Grading of Recommendations, Assessment, Development and Evaluation). ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Large (>10 000 participants) or population based or multisite observational studies and surveillance data (incidence and risk factors) reporting on confirmed myocarditis or pericarditis after covid-19 mRNA vaccination; case series (n≥5, presentation, short term clinical course and longer term outcomes); opinions, letters, reviews, and primary studies focused on describing or supporting hypothesised mechanisms. RESULTS: 46 studies were included (14 on incidence, seven on risk factors, 11 on characteristics and short term course, three on longer term outcomes, and 21 on mechanisms). Incidence of myocarditis after mRNA vaccines was highest in male adolescents and male young adults (age 12-17 years, range 50-139 cases per million (low certainty); 18-29 years, 28-147 per million (moderate certainty)). For girls and boys aged 5-11 years and women aged 18-29 years, incidence of myocarditis after vaccination with BNT162b2 (Pfizer/BioNTech) could be fewer than 20 cases per million (low certainty). Incidence after a third dose of an mRNA vaccine had very low certainty evidence. For individuals of 18-29 years, incidence of myocarditis is probably higher after vaccination with mRNA-1273 (Moderna) compared with Pfizer (moderate certainty). Among individuals aged 12-17, 18-29, or 18-39 years, incidence of myocarditis or pericarditis after dose two of an mRNA vaccine for covid-19 might be lower when administered ≥31 days compared with ≤30 days after dose one (low certainty). Data specific to men aged 18-29 years indicated that the dosing interval might need to increase to ≥56 days to substantially drop myocarditis or pericarditis incidence. For clinical course and short term outcomes, only one small case series (n=8) was found for 5-11 year olds. In adolescents and adults, most (>90%) myocarditis cases involved men of a median 20-30 years of age and with symptom onset two to four days after a second dose (71-100%). Most people were admitted to hospital (≥84%) for a short duration (two to four days). For pericarditis, data were limited but more variation than myocarditis has been reported in patient age, sex, onset timing, and rate of admission to hospital. Three case series with longer term (3 months; n=38) follow-up suggested persistent echocardiogram abnormalities, as well as ongoing symptoms or a need for drug treatments or restriction from activities in >50% of patients. Sixteen hypothesised mechanisms were described, with little direct supporting or refuting evidence. CONCLUSIONS: These findings indicate that adolescent and young adult men are at the highest risk of myocarditis after mRNA vaccination. Use of a Pfizer vaccine over a Moderna vaccine and waiting for more than 30 days between doses might be preferred for this population. Incidence of myocarditis in children aged 5-11 years is very rare but certainty was low. Data for clinical risk factors were very limited. A clinical course of mRNA related myocarditis appeared to be benign, although longer term follow-up data were limited. Prospective studies with appropriate testing (eg, biopsy and tissue morphology) will enhance understanding of mechanism.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Pillay J, Gaudet L, Wingert A, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ. 2022. PMID: 35830976. doi:10.1136/bmj-2021-069445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。